Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−48.61 M USD
204.00 K USD
40.23 M
About CG Oncology, Inc.
Sector
Industry
CEO
Arthur Kuan
Website
Headquarters
Irvine
Founded
2010
FIGI
BBG00YHKK4Q3
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CGON is 39.94 USD — it has increased by 2.25% in the past 24 hours. Watch CG Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange CG Oncology, Inc. stocks are traded under the ticker CGON.
CGON stock has risen by 11.91% compared to the previous week, the month change is a 15.13% rise, over the last year CG Oncology, Inc. has showed a 37.72% increase.
We've gathered analysts' opinions on CG Oncology, Inc. future price: according to them, CGON price has a max estimate of 86.00 USD and a min estimate of 52.00 USD. Watch CGON chart and read a more detailed CG Oncology, Inc. stock forecast: see what analysts think of CG Oncology, Inc. and suggest that you do with its stocks.
CGON reached its all-time high on Feb 16, 2024 with the price of 50.23 USD, and its all-time low was 25.77 USD and was reached on May 13, 2024. View more price dynamics on CGON chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CGON stock is 3.31% volatile and has beta coefficient of 0.91. Track CG Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is CG Oncology, Inc. there?
Today CG Oncology, Inc. has the market capitalization of 2.68 B, it has decreased by −0.36% over the last week.
Yes, you can track CG Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
CG Oncology, Inc. is going to release the next earnings report on Nov 27, 2024. Keep track of upcoming events with our Earnings Calendar.
CGON earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.36 USD resulting in a 21.35% surprise. The estimated earnings for the next quarter are −0.36 USD per share. See more details about CG Oncology, Inc. earnings.
CG Oncology, Inc. revenue for the last quarter amounts to 111.00 K USD, despite the estimated figure of 209.67 K USD. In the next quarter, revenue is expected to reach 205.40 K USD.
CGON net income for the last quarter is −18.90 M USD, while the quarter before that showed −16.93 M USD of net income which accounts for −11.63% change. Track more CG Oncology, Inc. financial stats to get the full picture.
No, CGON doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 61.00 employees. See our rating of the largest employees — is CG Oncology, Inc. on this list?
Like other stocks, CGON shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CG Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CG Oncology, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CG Oncology, Inc. stock shows the strong buy signal. See more of CG Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.